Edition:
United Kingdom

Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

8.10USD
5:58pm GMT
Change (% chg)

$0.08 (+0.93%)
Prev Close
$8.02
Open
$7.95
Day's High
$8.15
Day's Low
$7.80
Volume
47,146
Avg. Vol
159,699
52-wk High
$17.20
52-wk Low
$7.00

Chart for

About

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development... (more)

Overall

Beta: 1.84
Market Cap(Mil.): $831.83
Shares Outstanding(Mil.): 53.67
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Cytokinetics Qtrly Net Loss Per Share $0.75

* CYTOKINETICS, INC. REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

15 Feb 2018

BRIEF-Cytokinetics Announces Progress Against Vision 2020

* CYTOKINETICS INC - ‍RESULTS FROM FOUR CLINICAL TRIALS OF CK-2127107 EXPECTED IN 2018​

03 Jan 2018

Cytokinetics sinks on abandoning ALS drug after failed trial

Cytokinetics Inc shares plummeted nearly 28 percent on Tuesday after the drugmaker said it would stop developing one of its treatments for ALS, a fatal neuro-degenerative disorder, after the drug failed to improve lung function in a key trial.

21 Nov 2017

UPDATE 4-Cytokinetics sinks on abandoning ALS drug after failed trial

Nov 21 Cytokinetics Inc shares plummeted nearly 28 percent on Tuesday after the drugmaker said it would stop developing one of its treatments for ALS, a fatal neuro-degenerative disorder, after the drug failed to improve lung function in a key trial.

21 Nov 2017

BRIEF-Cytokinetics Inc announces negative results from VITALITY-ALS

* Phase 3 clinical trial of Tirasemtiv in patients with ALS did not meet primary or secondary endpoints​

21 Nov 2017

Cytokinetics' neuro-degenerative drug fails late-stage trial

Nov 21 Cytokinetics Inc said on Tuesday its drug to treat a type of neuro-degenerative disorder failed to meet the main goal of a late-stage trial.

21 Nov 2017

BRIEF-Cytokinetics files for potential mixed shelf, size undisclosed‍​

* Cytokinetics Inc files for potential mixed shelf, size undisclosed - SEC Filing ‍​ Source text: http://bit.ly/2hauCBo Further company coverage:

03 Nov 2017

BRIEF-Cytokinetics enters into second amendment to certain loan and security agreement

* Cytokinetics - ‍on Oct 27, entered into second amendment to certain loan and security agreement dated as of October 19, 2015

31 Oct 2017

BRIEF-Cytokinetics reports Q3 loss of ‍$0.60/shr​

* Cytokinetics, Inc. reports third quarter 2017 financial results

26 Oct 2017

BRIEF-Cytokinetics announces dosing of first patient in Japan in phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure

* Cytokinetics announces dosing of first patient in Japan in GALACTIC-HF, phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure

19 Sep 2017

Earnings vs. Estimates